期刊论文

Zhao, J.

中文

中南大学学报(医学版)

1672-7347

2013

38

4

365-369

10.3969/j.issn.1672-7347.2013.04.005

2009年教育部博士点基金（20090162110012）.感谢美国辉瑞公司对本研究提供资金资助.该公司未参与本研究的任何工作,所有研究数据的记录、录入和分析,以及对研究结果的解释均由研究者独立进行.

本校为第一机构

目的: 比较齐拉西酮和奥氮平对首发精神分裂症患者糖脂代谢的影响。方法: 260名患者随机分为齐拉西酮组和奥氮平组,治疗观察6周。测量患者基线、第2周末、第4周末和第6周末时体质量,并计算体质量指数。基线和治疗终点时采集空腹血测量空腹血糖、空腹胰岛素、高密度脂蛋白、胆固醇和三酰甘油,并计算胰岛素抵抗指数,部分患者检测了治疗前后的低密度脂蛋白。结果: 共有245名患者完成研究,齐拉西酮组121例,奥氮平组124例。齐拉西酮剂量137.5 mg/d,奥氮平剂量19.5 mg/d。治疗6周末,奥氮平组[(4.55±3.37) kg]的体质量增加显著高于齐拉西酮组[(-0.83±2.05) kg,P

OBJECTIVE: To investigate the effect of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia. METHODS: A total of 260 schizophrenics were assigned randomly to receive ziprasidone or olanzapine for 6 weeks. The weight was measured at baseline, week 2, 4 and 6. Fasting blood glucose (FBS), fasting insulin, high-density lipoprotein (HDL), total-cholesterol (TC) and triglycerides (TG) were measured at baseline and the end of 6-week treatment. Low-density lipoprotein (LDL) was measured in some patients at baseline and the end of 6-week treatment. Body mass index...